https://catalogues.ema.europa.eu/node/4757/study-documents
Patient Characteristics and Elranatamab administration patterns of Real-World Patients Receiving...
real worldpatientcharacteristicselranatamabadministration
https://hematoonkologia.pl/elranatamab/id/6801-elranatamab-w-leczeniu-opornego-lub-nawrotowego-szpiczaka-plazmocytowego-wyniki-badania
Elranatamab w leczeniu opornego lub nawrotowego szpiczaka plazmocytowego – wyniki badania 2 fazy...
Hematoonkologia.pl - portal edukacyjny zajmujący się tematyką rozrostowych chorób hematologicznych skierowany do lekarzy i pacjentów.
elranatamableczeniulubwynikibadania
https://www.onclive.com/view/dr-byun-on-updated-data-from-melt-mm-with-mezigdomide-and-elranatamab-in-multiple-myeloma
Dr Byun on Updated Data From MELT-MM With Mezigdomide and Elranatamab in Multiple Myeloma | OncLive
Oct 16, 2026 - Ja Min Byun, MD, PhD, discusses updated phase 1 findings with mezigdomide plus elranatamab in relapsed/refractory multiple myeloma.
multiple myelomabyunupdateddatamelt
https://www.page-meeting.org/Abstracts/elranatamab-exposure-safety-analysis-in-patients-with-relapse-or-refractory-multiple-myeloma-insights-from-magnetismm-studies/
Elranatamab Exposure-Safety Analysis in Patients with Relapse or Refractory Multiple Myeloma:...
Oct 21, 2025 - Poster: Drug/Disease Modelling - Oncology - Elranatamab Exposure-Safety Analysis in Patients with Relapse or Refractory Multiple Myeloma: Insights from...
multiple myelomaelranatamabexposuresafetyanalysis
https://rarecancernews.com/elrexfio-elranatamab-bcmm-multiple-myeloma/
Elrexfio (elranatamab-bcmm) for multiple myeloma | Rare Cancer News
Jun 1, 2026 - Elrexfio (elranatamab-bcmm) is an injectable therapy approved in the U.S. for RRMM adults given at least four previous lines of therapy.
multiple myelomacancer newselrexfioelranatamabbcmm